Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 2/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216047 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1POLBMAPTMEN1 | |
| SCHEMBL3932081 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1POLBMAPTMEN1 | |
| SCHEMBL4579551 | 0.93 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1POLBMAPTMEN1 | |
| SCHEMBL4579546 | 0.93 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1POLBMAPTMEN1 | |
| SCHEMBL8343112 | 0.86 | PREP (0.53) | ALDH1A1CTSLCTSBGAANAAA | |
| SCHEMBL22076255 | 0.85 | CTSL (0.55) | ALDH1A1MAPTCTSLCTSBGAA | |
| SCHEMBL29048164 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1POLBMAPTMEN1 | |
| SCHEMBL13017770 | 0.84 | NAAA (0.50) | ALDH1A1CTSLCTSBGAANAAA | |
| SCHEMBL12345121 | 0.84 | NAAA (0.50) | ALDH1A1CTSLCTSBGAANAAA | |
| SCHEMBL8342642 | 0.82 | GAA (0.63) | SMN1; SMN2ALDH1A1POLBMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511154-B2 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICALS AG (CH) | 2009-03-31 | — | — | US | disclosed |
| US-20080009637-A1 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG | 2008-01-10 | — | — | US | disclosed |
| US-7262307-B2 | 1′-benzyl-3-bromo-[1,3′]bipyrrolidinyl-2-one | BASILEA PHARMACEUTICA AG (CH) | 2007-08-28 | — | — | US | disclosed |
| EP-1311518-B1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| US-20050070722-A1 | 1'-Benzyl-3-bromo-[1,3']bipyrrolidinyl-2-one | BASILEA PHARMACEUTICA AG (CH) | 2005-03-31 | — | — | US | disclosed |
| US-6828442-B2 | Coupling N-benzyl-3-pyrrolidinamine compound with acyl halide; cyclization in presence of a base; reacting with triphenylphosphine to obtain phosphonium salt; reacting with di-tert. -butyl-dicarbonate under hydrogenation conditions | BASILEA PHARMACEUTICA AG (CH) | 2004-12-07 | — | — | US | disclosed |
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG (CH) | 2003-10-16 | — | — | US | disclosed |
| EP-1311518-A1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | Basilea Pharmaceutica AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002014332-A1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009637-A1 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | PNKP, PNISR, CLK3 | SMN1; SMN2 3397/4885ALDH1A1 4439/4885POLB 238/4885 |
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | PNKP, PHOSPHO1, PTMS | SMN1; SMN2 3317/4885ALDH1A1 4354/4885POLB 235/4885 |
| US-20050070722-A1 | 1'-Benzyl-3-bromo-[1,3']bipyrrolidinyl-2-one | BRD1, BRD4, BET1 | SMN1; SMN2 3644/4885ALDH1A1 1143/4885POLB 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.